Riociguat Tablet, Film Coated
Product Images NDC 70710-2159

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Riociguat (NDC 70710-2159). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Riociguat-0-5mg-90s-cntnr-label (Riociguat 0 5mg 90s Cntnr Label)

Riociguat Tablets, USP 0.5 mg film coated tablets label showing a package containing 90 tablets. The label includes usage instructions, storage information, manufacturer MSN Laboratories Private Limited, and distributor Zydus Pharmaceuticals USA Inc, Pennington, NJ. It features barcodes, NDC 70710-2156-9, and advises pharmacists to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

Riociguat-1-5mg-90s-cntnr-label (Riociguat 1 5mg 90s Cntnr Label)

Riociguat Tablets USP 1.5 mg film-coated oral tablets label from Zydus Pharmaceuticals USA Inc. The label states 90 tablets in the package with prescription-only status. It includes storage instructions, manufacturer and distributor information, a barcode, and a reminder to dispense the Medication Guide to each patient.*

FDA Label Image

Riociguat-1mg-90s-cntnr-label (Riociguat 1mg 90s Cntnr Label)

Riociguat Tablets, USP 1 mg film-coated tablets label with NDC 70710-2157-9. The label states the product contains riociguat USP 1 mg per tablet and is supplied as 90 tablets. It includes storage instructions and manufacturer information, listing MSN Laboratories Private Limited as manufacturer and Zydus Pharmaceuticals (USA) Inc. as distributor. The label also advises dispensing the Medication Guide to each patient and shows a barcode and revision date 04/26.*

FDA Label Image

Riociguat-2-5mg-90s-cntnr-label (Riociguat 2 5mg 90s Cntnr Label)

Packaging label for Riociguat Tablets USP 2.5 mg film-coated tablets. The label states there are 90 tablets in the bottle. It includes manufacturer information (MSN Laboratories Private Limited) and distributor details (Zydus Pharmaceuticals USA Inc). The label also shows storage instructions and a reminder to dispense the Medication Guide to each patient.*

FDA Label Image

Riociguat-2mg-90s-cntnr-label (Riociguat 2mg 90s Cntnr Label)

Label for Riociguat Tablets USP 2 mg, film-coated oral tablets. The label indicates the package contains 90 tablets and is for prescription use only. Manufactured by MSN Laboratories Private Limited and distributed by Zydus Pharmaceuticals (USA) Inc. Includes storage instructions and a note to dispense the accompanying medication guide to patients.*

FDA Label Image

Riociguat-birth-control-chart (Riociguat Birth Control Chart)

An instructional diagram showing four contraceptive method options. Each option lists combinations of methods such as intrauterine systems, standard intrauterine devices, tubal sterilization, progesterone implant, hormonal contraceptives (oral, patch, ring, injection), and barrier methods including male condom, diaphragm, and cervical cap with spermicide. Partner's vasectomy is also included in one option.*

FDA Label Image

Figure-01 (Riociguat Figure 01)

This is a chart showing point estimates and 90% confidence intervals for Riociguat and its metabolite M1. It depicts changes relative to reference in pharmacokinetic parameters AUC and Cmax across variables such as hepatic impairment, renal impairment, age groups, and gender, with data represented as dots for AUC and triangles for Cmax.*

FDA Label Image

Figure-02 (Riociguat Figure 02)

A scientific chart depicting the effect of various factors (e.g., CYP inhibitors, antacids, smoking) on Riociguat and its metabolite M1 pharmacokinetics, showing point estimates and 90% confidence intervals for AUC and Cmax changes relative to reference, along with dosing recommendations such as dose adjustment or administration separation.*

FDA Label Image

Fig-03 (Riociguat Figure 03)

A line graph depicting change from baseline to last visit in 6-minute walk distance (meters) over time in weeks. Two lines compare Riociguat and placebo, with Riociguat showing a steady increase in walk distance up to 16 weeks, while placebo shows a smaller increase peaking around 6 weeks then declining.*

FDA Label Image

Fig-04 (Riociguat Figure 04)

A bar chart comparing the percentage of patients treated with Riociguat versus placebo based on the change from baseline to the last visit in 6-minute walk distance (meters). The x-axis shows ranges of change in meters from worsening to improvement, and the y-axis shows the percentage of patients. Riociguat data is represented by black bars, placebo by white bars.*

FDA Label Image

Fig-05 (Riociguat Figure 05)

A horizontal forest plot chart illustrating the mean change in 6-minute walk distance (6MWD) comparing placebo and Riociguat across different patient subgroups: Inoperable CTEPH, Postoperative CTEPH, WHO I/II at Baseline, WHO III/IV at Baseline, and Overall. The plot shows number of patients per subgroup and confidence intervals of the least squares difference in means favoring placebo or Riociguat.*

FDA Label Image

Fig-06 (Riociguat Figure 06)

A line graph comparing the change from baseline to last visit in 6-minute walk distance (meters) over 12 weeks for Riociguat and placebo groups. The x-axis represents weeks (0 to 12), and the y-axis represents the change in meters. Riociguat shows a steady increase and higher improvement over time compared to placebo.*

FDA Label Image

Fig-07 (Riociguat Figure 07)

A bar chart comparing the percentage of patients treated with Riociguat versus placebo, showing change from baseline in 6-minute walk distance (in meters). The x-axis represents intervals of meters changed, ranging from worsening (negative values) to improvement (positive values). The y-axis shows the percentage of patients, with two differently shaded bars representing Riociguat (black) and placebo (white) groups.*

FDA Label Image

Fig-08 (Riociguat Figure 08)

A forest plot chart displaying mean changes in 6-minute walking distance (6MWD) comparing Placebo and Riociguat across various patient subgroups and baseline conditions. The chart shows number of patients, mean changes for placebo and Riociguat, and least squares differences with 95% confidence intervals, indicating treatment effect favoring Riociguat.*

FDA Label Image

Fig-09 (Riociguat Figure 09)

A line graph depicting the percentage of patients with disease progression over 84 days for Riociguat and placebo groups. The x-axis represents days, and the y-axis shows the percentage of patients with disease progression. The Riociguat group displays a consistently lower progression percentage compared to placebo.*

FDA Label Image

Rio-structure (Riociguat Structure)

Chemical structure of Riociguat, showing its molecular arrangement with elements including nitrogen, oxygen, carbon, hydrogen, and fluorine. The structure features a multi-ring system with functional groups consistent with the Riociguat molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.